Home About Us Management Product Pipeline Collaborators Contact Us

About Us; Our Programs

Zoltan Laboratories, LLC is developing recombinant PLAP for reducing or even reversing muscle wasting and key metabolic disorders caused by cancer, cancer treatments, obesity, diabetes, and/or old age. Older people who have cancer or are obese and/or type 2 diabetic are in the greatest need to control muscle wasting by PLAP.

The project of primary importance is to use injected PLAP to prevent loss of muscle proteins and improve bone marrow function in cancer patients treated with chemotherapy and/or radiation therapy.

In the second project, the elderly as well as obese and type 2 diabetic people are treated with oral PLAP to reduce wasting of muscle proteins and muscle strength along with reducing dyslipidemia, obesity, insulin resistance, and hyperinsulinemia.

PLAP is also being developed to promote diabetic wound healing as well as for the treatment of inflammatory/infections skin conditions (acne, shingles, herpes, psoriasis) and, along with a small compound, necrotic pancreatitis and ensuing type 3c diabetes.